A striking observation from our analysis that supports a pathogenic role for loss-of-function SHP2 mutations is that all documented SHP2 liver cancer mutants were neutral or loss-of-activity in our dataset (Figure 3C and Supplementary Table 5). The gene discussed is PTPN11; the disease is liver cancer.